Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation

[1]  M. Krajinovic,et al.  Association of CTH variant with sinusoidal obstruction syndrome in children receiving intravenous busulfan and cyclophosphamide before hematopoietic stem cell transplantation , 2016, The Pharmacogenomics Journal.

[2]  P. Richardson,et al.  Timing of Initiation of Defibrotide Post-Diagnosis of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome Post-Hematopoietic Stem Cell Transplantation: Exploratory Age-Group Analysis from an Expanded Access Study , 2016 .

[3]  A. Egberts,et al.  Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis. , 2016, The Lancet. Haematology.

[4]  P. Richardson,et al.  Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease: Final Results From the International Compassionate-Use Program. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[5]  A. Randolph,et al.  High Variability in the Reported Management of Hepatic Veno-Occlusive Disease in Children after Hematopoietic Stem Cell Transplantation. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[6]  M. Koçak,et al.  High Incidence of Veno‐Occlusive Disease With Myeloablative Chemotherapy Following Craniospinal Irradiation in Children With Newly Diagnosed High‐Risk CNS Embryonal Tumors: A Report From the Children's Oncology Group (CCG‐99702) , 2016, Pediatric blood & cancer.

[7]  M. Díaz-Ricart,et al.  What is going on between defibrotide and endothelial cells? Snapshots reveal the hot spots of their romance. , 2016, Blood.

[8]  R. D'Agostino,et al.  Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure. , 2016, Blood.

[9]  T. Miyamoto,et al.  Sinusoidal obstruction syndrome after allogeneic hematopoietic stem cell transplantation: Incidence, risk factors and outcomes , 2016, Bone Marrow Transplantation.

[10]  L. Luznik,et al.  Modern approaches to HLA-haploidentical blood or marrow transplantation. , 2016, Nature Reviews Clinical Oncology.

[11]  P. Veys,et al.  European Society for Blood and Marrow Transplantation Analysis of Treosulfan Conditioning Before Hematopoietic Stem Cell Transplantation in Children and Adolescents With Hematological Malignancies , 2016, Pediatric blood & cancer.

[12]  S. Hanash,et al.  Biomarkers for Diagnosis and Prognosis of Sinusoidal Obstruction Syndrome after Hematopoietic Cell Transplantation. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[13]  M. Abecassis,et al.  Sinusoidal obstruction syndrome/veno-occlusive disease: current situation and perspectives—a position statement from the European Society for Blood and Marrow Transplantation (EBMT) , 2015, Bone Marrow Transplantation.

[14]  K. Myers,et al.  Veno-occlusive disease of the liver in the absence of elevation in bilirubin in pediatric patients after hematopoietic stem cell transplantation. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[15]  E. Carreras.  How I manage sinusoidal obstruction syndrome after haematopoietic cell transplantation , 2015, British journal of haematology.

[16]  S. Suzuki,et al.  High-dose chemotherapy for high-risk retinoblastoma: clinical course and outcome of 14 cases in the National Cancer Center, Japan , 2015, Bone Marrow Transplantation.

[17]  R. Bajwa,et al.  Anicteric Hepatic Veno-Occlusive Disease after Hematopoietic Stem Cell Transplantation in Children , 2014 .

[18]  B. Gruhn,et al.  Heparanase polymorphisms: influence on incidence of hepatic sinusoidal obstruction syndrome in children undergoing allogeneic hematopoietic stem cell transplantation , 2015, Journal of Cancer Research and Clinical Oncology.

[19]  J. Crawford,et al.  Sinusoidal obstruction syndrome (hepatic veno-occlusive disease). , 2014, Journal of Clinical and Experimental Hepatology.

[20]  P. Stepensky,et al.  Incidence and risk factors for moderate-to-severe veno-occlusive disease of the liver after allogeneic stem cell transplantation using a reduced intensity conditioning regimen , 2014, Bone Marrow Transplantation.

[21]  P. Chevallier,et al.  Continuous reduced nonrelapse mortality after allogeneic hematopoietic stem cell transplantation: a single-institution's three decade experience. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[22]  N. Chao.  How I treat sinusoidal obstruction syndrome. , 2014, Blood.

[23]  H. Mugishima,et al.  Prospective pharmacokinetic study of intravenous busulfan in hematopoietic stem cell transplantation in 25 children , 2014, Pediatric transplantation.

[24]  Yi-Xiang J. Wang,et al.  Hepatic Sinusoidal Obstruction Syndrome Caused by Herbal Medicine: CT and MRI Features , 2014, Korean journal of radiology.

[25]  N. Krivoy,et al.  MTHFR C677T/A1298C genotype: a possible risk factor for liver sinusoidal obstruction syndrome , 2014, Bone Marrow Transplantation.

[26]  Y. Daali,et al.  The association of cytochrome P450 genetic polymorphisms with sulfolane formation and the efficacy of a busulfan-based conditioning regimen in pediatric patients undergoing hematopoietic stem cell transplantation , 2013, The Pharmacogenomics Journal.

[27]  N. Kröger,et al.  Allogeneic hematopoietic SCT for adults AML using i.v. BU in the conditioning regimen: outcomes and risk factors for the occurrence of hepatic sinusoidal obstructive syndrome , 2014, Bone Marrow Transplantation.

[28]  J. Dipersio,et al.  Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation. , 2013, Blood.

[29]  P. Veys,et al.  BCSH/BSBMT guideline: diagnosis and management of veno‐occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation , 2013, British journal of haematology.

[30]  M. Díaz-Ricart,et al.  Distinct deleterious effects of cyclosporine and tacrolimus and combined tacrolimus-sirolimus on endothelial cells: protective effect of defibrotide. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[31]  H. Kantarjian,et al.  Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia , 2013, Cancer.

[32]  H. Kantarjian,et al.  Feasibility of allografting in patients with advanced acute lymphoblastic leukemia after salvage therapy with inotuzumab ozogamicin. , 2013, Clinical lymphoma, myeloma & leukemia.

[33]  A. Paci,et al.  Busulfan pharmacokinetics following intravenous and oral dosing regimens in children receiving high-dose myeloablative chemotherapy for high-risk neuroblastoma as part of the HR-NBL-1/SIOPEN trial. , 2012, European journal of cancer.

[34]  J. Scarisbrick,et al.  Organ‐specific management and supportive care in chronic graft‐versus‐host disease , 2012, British journal of haematology.

[35]  He Huang,et al.  Defibrotide for the prevention of hepatic veno‐occlusive disease after hematopoietic stem cell transplantation: a systematic review , 2012, Clinical transplantation.

[36]  A. Schulz,et al.  Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial , 2012, The Lancet.

[37]  Bradley A George,et al.  Tandem stem cell rescue as consolidation therapy for high‐risk neuroblastoma , 2012, Pediatric blood & cancer.

[38]  P. O’Donnell,et al.  Clinicopathologic features of late-onset veno-occlusive disease/sinusoidal obstruction syndrome after high dose intravenous busulfan and hematopoietic cell transplant , 2012, Leukemia & lymphoma.

[39]  Myeong-Jin Kim,et al.  Accuracy of gadoxetic acid-enhanced magnetic resonance imaging for the diagnosis of sinusoidal obstruction syndrome in patients with chemotherapy-treated colorectal liver metastases , 2012, European Radiology.

[40]  M. Díaz-Ricart,et al.  Combining allografting with mTOR inhibitors for metastatic renal cell cancer , 2011, Bone Marrow Transplantation.

[41]  M. Díaz-Beyá,et al.  The incidence of veno-occlusive disease following allogeneic hematopoietic stem cell transplantation has diminished and the outcome improved over the last decade. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[42]  K. Rentsch,et al.  Therapeutic drug monitoring is essential for intravenous busulfan therapy in pediatric hematopoietic stem cell recipients , 2011, Pediatric transplantation.

[43]  R. Alaggio,et al.  Veno‐occlusive disease in pediatric patients affected by Wilms tumor , 2011, Pediatric blood & cancer.

[44]  L. Lehmann,et al.  Safety and Utility of Liver Biopsy After Pediatric Hematopoietic Stem Cell Transplantation , 2011, Journal of pediatric hematology/oncology.

[45]  J. Sosna,et al.  Radiologic imaging and intervention for gastrointestinal and hepatic complications of hematopoietic stem cell transplantation. , 2011, Radiology.

[46]  H. Halkin,et al.  Linearity and stability of intravenous busulfan pharmacokinetics and the role of glutathione in busulfan elimination. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[47]  R. Riccardi,et al.  Hepatic Veno-Occlusive Disease , 2010, Paediatric drugs.

[48]  P. Richardson,et al.  Prediction of veno-occlusive disease using biomarkers of endothelial injury. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[49]  Allen R. Chen,et al.  Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[50]  A. Bleyer,et al.  Oral 6-mercaptopurine versus oral 6-thioguanine and veno-occlusive disease in children with standard-risk acute lymphoblastic leukemia: report of the Children's Oncology Group CCG-1952 clinical trial. , 2010, Blood.

[51]  Kunihiko Kobayashi,et al.  Plasma protein C is a useful clinical marker for hepatic veno‐occlusive disease (VOD) in stem cell transplantation , 2010, Pediatric blood & cancer.

[52]  Allen R. Chen,et al.  Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[53]  L. Bouzas,et al.  Serum ferritin as risk factor for sinusoidal obstruction syndrome of the liver in patients undergoing hematopoietic stem cell transplantation. , 2009, Blood.

[54]  P. Richardson,et al.  Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation. , 2008, Blood.

[55]  P. Robinson,et al.  Sinusoidal obstructive syndrome diagnosed with superparamagnetic iron oxide-enhanced magnetic resonance imaging in patients with chemotherapy-treated colorectal liver metastases. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  E. Hod,et al.  Platelet Transfusion Refractoriness , 2024, Plasmatology.

[57]  M. Terol,et al.  Veno-occlusive disease of the liver after high-dose cytoreductive therapy with busulfan and melphalan for autologous blood stem cell transplantation in multiple myeloma patients. , 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[58]  Y. Lau,et al.  Risk factors and mortality predictors of hepatic veno-occlusive disease after pediatric hematopoietic stem cell transplantation , 2007, Bone Marrow Transplantation.

[59]  B. George,et al.  A new stratification strategy that identifies a subset of class III patients with an adverse prognosis among children with beta thalassemia major undergoing a matched related allogeneic stem cell transplantation. , 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[60]  G. Morgan,et al.  Prophylactic defibrotide in allogeneic stem cell transplantation: minimal morbidity and zero mortality from veno-occlusive disease , 2007, Bone Marrow Transplantation.

[61]  C. Bennett,et al.  Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project. , 2007, Leukemia research.

[62]  L. Dupuis,et al.  Pharmacokinetic disposition and clinical outcomes in infants and children receiving intravenous busulfan for allogeneic hematopoietic stem cell transplantation. , 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[63]  A. Schulz,et al.  Stem cell transplantation in children with infantile osteopetrosis is associated with a high incidence of VOD, which could be prevented with defibrotide , 2006, Bone Marrow Transplantation.

[64]  Sukru Mehmet Erturk,et al.  CT features of hepatic venoocclusive disease and hepatic graft-versus-host disease in patients after hematopoietic stem cell transplantation. , 2006, AJR. American journal of roentgenology.

[65]  M. Elli,et al.  Veno‐occlusive disease of the liver in a child after chemotherapy for brain tumor , 2006, Pediatric blood & cancer.

[66]  A. Fischer,et al.  Hematopoietic Stem Cell Transplantation in Hemophagocytic Lymphohistiocytosis: A Single-Center Report of 48 Patients , 2006, Pediatrics.

[67]  A. Helmy.  Review article: updates in the pathogenesis and therapy of hepatic sinusoidal obstruction syndrome , 2006, Alimentary pharmacology & therapeutics.

[68]  M. Higuchi,et al.  Demonstration of reversed flow in segmental branches of the portal vein with hand-held color Doppler ultrasonography after hematopoietic stem cell transplantation , 2005, Bone Marrow Transplantation.

[69]  J. Haines,et al.  The hemochromatosis C282Y allele: a risk factor for hepatic veno-occlusive disease after hematopoietic stem cell transplantation , 2005, Bone Marrow Transplantation.

[70]  T. Gooley,et al.  Serum bilirubin levels and mortality after myeloablative allogeneic hematopoietic cell transplantation , 2005, Hepatology.

[71]  A. Girolami,et al.  Role of fibrinolytic and clotting parameters in the diagnosis of liver veno-occlusive disease after hematopoietic stem cell transplantation in a pediatric population , 2005, Thrombosis and Haemostasis.

[72]  A. Grañena,et al.  On the reliability of clinical criteria for the diagnosis of hepatic veno-occlusive disease , 1993, Annals of Hematology.

[73]  M. Pillon,et al.  A prospective survey on incidence, risk factors and therapy of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation. , 2005, Haematologica.

[74]  M. Sulis,et al.  Veno-Occlusive Disease in Pediatric Patients Receiving Actinomycin D and Vincristine Only for the Treatment of Rhabdomyosarcoma , 2004, Journal of pediatric hematology/oncology.

[75]  B. George,et al.  Glutathione S-transferase M1 polymorphism: a risk factor for hepatic venoocclusive disease in bone marrow transplantation. , 2004, Blood.

[76]  B. Chapuis,et al.  Prevention of veno-occlusive disease with defibrotide after allogeneic stem cell transplantation. , 2004, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[77]  B. V. Van Beers,et al.  MR imaging findings in a patient with hepatic veno-occlusive disease. , 2004, Acta gastro-enterologica Belgica.

[78]  J. Cornish,et al.  Prophylaxis with defibrotide prevents veno-occlusive disease in stem cell transplantation after gemtuzumab ozogamicin exposure. , 2004, Blood.

[79]  A. Schulz,et al.  Defibrotide in the treatment of children with veno-occlusive disease (VOD): a retrospective multicentre study demonstrates therapeutic efficacy upon early intervention , 2004, Bone Marrow Transplantation.

[80]  R. Storb,et al.  Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: a study of 193 patients. , 2004, Blood.

[81]  P. Richardson,et al.  Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. , 2003, Blood.

[82]  R. Sauve,et al.  Incidence, survival and risk factors for the development of veno-occlusive disease in pediatric hematopoietic stem cell transplant recipients , 2003, Bone Marrow Transplantation.

[83]  C. Solano,et al.  Positive selection for CD34+ reduces the incidence and severity of veno-occlusive disease of the liver after HLA-identical sibling allogeneic peripheral blood stem cell transplantation. , 2003, Experimental hematology.

[84]  J. Chang,et al.  Role of Plasminogen Activator Inhibitor-1 (PAI-1) Levels in the Diagnosis of BMT-associated Hepatic Veno-occlusive Disease and Monitoring of Subsequent Therapy with Defibrotide (DF) , 2003, Hematology.

[85]  Allen R. Chen,et al.  Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome. , 2002, Blood.

[86]  R. Brand,et al.  Prospective study of renal insufficiency after bone marrow transplantation , 2002, Pediatric Nephrology.

[87]  V. Kuoch,et al.  Hepatic venous pressure gradients measured by duplex ultrasound. , 2002, Clinical radiology.

[88]  N. Lassau,et al.  Prognostic value of doppler-ultrasonography in hepatic veno-occlusive disease: A Study of 71 Children , 2002, Transplantation.

[89]  A. Schulz,et al.  HLA-haploidentical blood progenitor cell transplantation in osteopetrosis. , 2002, Blood.

[90]  A. Mcmillan,et al.  Veno-occlusive disease of the liver in children with solid tumors undergoing autologous hematopoietic progenitor cell transplantation: a high incidence in patients with neuroblastoma , 2002, Bone Marrow Transplantation.

[91]  K. Chik,et al.  Haematopoietic stem cell transplantation for thalassaemia major in Hong Kong: prognostic factors and outcome , 2002, Bone Marrow Transplantation.

[92]  H. Van Vlierberghe,et al.  Hepatic veno-occlusive disease: MRI findings , 2002, Abdominal Imaging.

[93]  I. Jarque,et al.  Marked reduction in the incidence of hepatic veno-occlusive disease after allogeneic hematopoietic stem cell transplantation with CD34+ positive selection , 2001, Bone Marrow Transplantation.

[94]  S. Howard,et al.  Hepatic veno-occlusive disease in children undergoing bone-marrow transplantation: usefulness of sonographic findings , 2001, Pediatric Radiology.

[95]  J. Kowalczyk,et al.  Venoocclusive liver disease (VOD) as a complication of Wilms' tumour management in the series of consecutive 206 patients. , 2000, European journal of pediatric surgery : official journal of Austrian Association of Pediatric Surgery ... [et al] = Zeitschrift fur Kinderchirurgie.

[96]  T. Matsunaga,et al.  Predictive markers for hepatic veno-occlusive disease after hematopoietic stem cell transplantation in adults: a prospective single center study , 2000, Bone Marrow Transplantation.

[97]  S. Lehmann,et al.  N-acetylcysteine for hepatic veno-occlusive disease after allogeneic stem cell transplantation , 2000, Bone Marrow Transplantation.

[98]  M. A. van den Bosch,et al.  MR imaging findings in two patients with hepatic veno-occlusive disease following bone marrow transplantation , 2000, European radiology.

[99]  F. Hernández-Navarro,et al.  BMT: Serum Ferritin as Risk Factor for Veno-occlusive Disease of the Liver. Prospective Cohort Study. , 2000, Hematology.

[100]  Jung Lim Lee,et al.  Veno-occlusive disease of the liver after busulfan, melphalan, and thiotepa conditioning therapy: incidence, risk factors, and outcome. , 1999, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[101]  R. Sackstein,et al.  Late onset veno-occlusive disease following high-dose chemotherapy and stem cell transplantation , 1999, Bone Marrow Transplantation.

[102]  F. Hernández-Navarro,et al.  Serum Ferritin as Risk Factor for Veno-occlusive Disease of the Liver. Prospective Cohort Study. , 1999, Hematology.

[103]  A. Gratwohl,et al.  Incidence and Outcome of Hepatic Veno-Occlusive Disease After Blood or Marrow Transplantation: A Prospective Cohort Study of the European Group for Blood and Marrow Transplantation , 1998 .

[104]  Je-Hwan Lee,et al.  Relevance of proteins C and S, antithrombin III, von Willebrand factor, and factor VIII for the development of hepatic veno-occlusive disease in patients undergoing allogeneic bone marrow transplantation: a prospective study , 1998, Bone Marrow Transplantation.

[105]  D. Neuberg,et al.  Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population. , 1998, Blood.

[106]  A. Gratwohl,et al.  Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party. , 1998, Blood.

[107]  P. Ljungman,et al.  Norethisterone treatment, a major risk-factor for veno-occlusive disease in the liver after allogeneic bone marrow transplantation. , 1998, Blood.

[108]  J. Sambrano,et al.  Antithrombin-III for the treatment of chemotherapy-induced organ dysfunction following bone marrow transplantation , 1997, Bone Marrow Transplantation.

[109]  M. Steinbuch,et al.  Sonographic findings in bone marrow transplant patients with symptomatic hepatic venoocclusive disease. , 1997, Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine.

[110]  J. Bourhis,et al.  Hepatic veno-occlusive disease after myeloablative treatment and bone marrow transplantation: value of gray-scale and Doppler US in 100 patients. , 1997, Radiology.

[111]  T. Okamura,et al.  Changes in hemostatic parameters in hepatic veno-occlusive disease following bone marrow transplantation , 1997, Bone Marrow Transplantation.

[112]  W. Wilmanns,et al.  Plasminogen activator inhibitor-1 confirms the diagnosis of hepatic veno-occlusive disease in patients with hyperbilirubinemia after bone marrow transplantation. , 1997, Blood.

[113]  Jung Lim Lee,et al.  Treatment of hepatic venocclusive disease with recombinant human tissue plasminogen activator and heparin in 42 marrow transplant patients. , 1997, Blood.

[114]  F. Appelbaum,et al.  The Problem of Thrombocytopenia after Hematopoietic Stem Cell Transplantation , 1996, The oncologist.

[115]  P. Ljungman,et al.  Treatment of hepatic venoocclusive disease with recombinant human tissue plasminogen activator or orthotopic liver transplantation after allogeneic bone marrow transplantation. , 1996, Transplantation.

[116]  S. Goldberg,et al.  Treatment of hepatic veno-occlusive disease with low-dose tissue plasminogen activator: impact on coagulation profile. , 1996, Bone marrow transplantation.

[117]  J. Brink,et al.  Diagnosis of venoocclusive disease of the liver after bone marrow transplantation: value of duplex sonography. , 1995, AJR. American journal of roentgenology.

[118]  S. Bearman,et al.  The syndrome of hepatic veno-occlusive disease after marrow transplantation. , 1995, Blood.

[119]  T. Kofler,et al.  Utility of transvenous liver biopsies and wedged hepatic venous pressure measurements in sixty marrow transplant recipients. , 1995, Transplantation.

[120]  C. García-Cantón,et al.  Acute renal failure in patients following bone marrow transplantation: prevalence, risk factors and outcome. , 1995, American journal of nephrology.

[121]  C. Haioun,et al.  Influence of clinical status on the efficiency of stored platelet transfusion , 1994, British journal of haematology.

[122]  J. Vernant,et al.  Influence du statut clinique sur l'efficacité transfusionnelle des plaquettes conservées , 1993 .

[123]  G. Anderson,et al.  Venoocclusive disease of the liver: development of a model for predicting fatal outcome after marrow transplantation. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[124]  R. A. Castillo-Lara,et al.  Definitions for sepsis and organ failure. , 1993, JAMA.

[125]  G. McDonald,et al.  Veno-occlusive Disease of the Liver and Multiorgan Failure after Bone Marrow Transplantation: A Cohort Study of 355 Patients , 1993, Annals of Internal Medicine.

[126]  A. Grañena,et al.  Transjugular liver biopsy in BMT. , 1993, Bone marrow transplantation.

[127]  Gianni,et al.  Naturally occurring anticoagulants and bone marrow transplantation: plasma protein C predicts the development of venocclusive disease of the liver. , 1993, Blood.

[128]  R. Chopra,et al.  von Willebrand factor as a marker of endothelial cell activation following BMT. , 1992, Bone marrow transplantation.

[129]  C. Higano,et al.  Venocclusive disease of the liver: prospective study of US evaluation. , 1992, Radiology.

[130]  H. Shulman,et al.  Hepatic veno-occlusive disease--liver toxicity syndrome after bone marrow transplantation. , 1992, Bone marrow transplantation.

[131]  J. E. Carceller.  American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis , 1992, Critical care medicine.

[132]  W. Knaus,et al.  Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. , 1992, Chest.

[133]  J. Ritz,et al.  HEPATIC DYSFUNCTION FOLLOWING T‐CELL-DEPLETED ALLOGENEIC BONE MARROW TRANSPLANTATION , 1991, Transplantation.

[134]  E. Gluckman,et al.  Liver veno-occlusive disease after bone marrow transplantation changes in coagulation parameters and endothelial markers. , 1991, Thrombosis research.

[135]  M. Abu-Yousef,et al.  Doppler sonography: a noninvasive method for evaluation of hepatic venocclusive disease. , 1990, AJR. American journal of roentgenology.

[136]  J. Charboneau,et al.  Hepatic venocclusive disease after bone-marrow transplantation: diagnosis with duplex sonography. , 1988, AJR. American journal of roentgenology.

[137]  L. Grochow,et al.  VENOOCCLUSIVE DISEASE OF THE LIVER FOLLOWING BONE MARROW TRANSPLANTATION , 1987, Transplantation.

[138]  R. Zittoun,et al.  Thrombocytopenia in venocclusive disease after bone marrow transplantation or chemotherapy. , 1986, Blood.

[139]  Pankaj Sharma,et al.  Venocclusive Disease of the Liver after Bone Marrow Transplantation: Diagnosis, Incidence, and Predisposing Factors , 1984, Hepatology.